Two Sigma Advisers LP Takes $52,000 Position in Century Therapeutics, Inc. (NASDAQ:IPSC)

Two Sigma Advisers LP purchased a new position in shares of Century Therapeutics, Inc. (NASDAQ:IPSC) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 51,000 shares of the company’s stock, valued at approximately $52,000. Two Sigma Advisers LP owned approximately 0.06% of Century Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Marshall Wace LLP bought a new stake in shares of Century Therapeutics during the 4th quarter valued at $36,000. Jane Street Group LLC lifted its position in Century Therapeutics by 166.2% during the fourth quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock worth $49,000 after purchasing an additional 29,992 shares during the period. Sei Investments Co. bought a new stake in Century Therapeutics during the fourth quarter worth about $53,000. Bank of America Corp DE grew its stake in Century Therapeutics by 109.1% during the fourth quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock worth $67,000 after buying an additional 34,466 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in Century Therapeutics in the 4th quarter valued at about $87,000. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Stock Up 9.5%

NASDAQ IPSC opened at $0.62 on Monday. The company has a market capitalization of $53.10 million, a price-to-earnings ratio of -0.33 and a beta of 1.77. Century Therapeutics, Inc. has a twelve month low of $0.34 and a twelve month high of $3.46. The stock has a fifty day simple moving average of $0.52 and a 200 day simple moving average of $0.78.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings results on Thursday, May 15th. The company reported $0.89 EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $1.20. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%. The firm had revenue of $109.16 million for the quarter, compared to analyst estimates of $45.52 million. Research analysts expect that Century Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on IPSC. Piper Sandler reduced their target price on Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating on the stock in a report on Thursday, March 20th. Guggenheim reiterated a “buy” rating on shares of Century Therapeutics in a research report on Friday, March 28th. Chardan Capital decreased their target price on shares of Century Therapeutics from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Friday, May 16th. Finally, HC Wainwright lowered their price target on shares of Century Therapeutics from $5.00 to $2.00 and set a “buy” rating for the company in a report on Thursday, April 3rd. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $4.20.

Century Therapeutics Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.